Dianthus Therapeutics DNTH Business Segments
| TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | TTM Q4 '24 | TTM Q3 '24 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Product | ||||||
| Discovery Expenses | $1.54M-28.7% | $2.17M-13.6% | $2.51M+18.5% | $2.12M+2.7% | $2.06M+19.0% | |
| Personnel And Related Costs | $25.11M+2.1% | $24.59M+10.1% | $22.33M+10.8% | $20.15M+69.4% | $11.89M-1.9% | |
| General And Administrative Expense by Product | ||||||
| Other Costs | $9.4M+0.5% | $9.36M+6.1% | $8.82M-6.5% | $9.43M+8.3% | $8.7M+7.3% | |
| Personnel And Related Costs | $11.75M+19.2% | $9.86M+9.3% | $9.03M+7.9% | $8.36M-22.3% | $10.76M+24.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Dianthus Therapeutics break its business down?
- Dianthus Therapeutics (DNTH) reports research and development expense by product across 4 parts — Discovery Expenses, Other Costs, Personnel And Related Costs and Share Based Compensation Expense. Each is extracted from the segment footnotes and tracked over time.
- Where does Dianthus Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Dianthus Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.